📜 What This Document Is

This is a 6-K filing, which is a report foreign companies (like OKYO, based in the UK) submit to the SEC to announce major news. This specific filing is a press release sharing updates about an upcoming scientific conference.

👉 In simple terms, it's a company news announcement that's also filed with regulators.

🏢 What The Company Does

OKYO Pharma is a clinical-stage biopharmaceutical company. They are focused on creating new drugs for eye diseases.

👉 Their main mission is to develop treatments for neuropathic corneal pain (NCP) and inflammatory eye conditions. They are currently in the testing phase for their lead drug candidate, not yet selling any approved products.

🧪 The Pipeline & Key Drug: Urcosimod

The company's primary drug under development is called urcosimod (formerly known as OK-101). It's designed to treat NCP, a severe and chronic eye pain condition.

👉 Why it matters: There are no FDA-approved therapies specifically for NCP. Patients currently rely on off-label treatments that often don't work well, so urcosimod is aiming to fill a major gap in care. It has received Fast Track designation from the FDA, which can speed up its development and review.

🎤 The Conference Update

OKYO announced two major activities at the prestigious 2026 ASCRS Annual Meeting in Washington, DC:

A Scientific Advisory Board (SAB) meeting with top eye experts to discuss urcosimod's data and plan their next clinical trial.
A formal data presentation of the Phase 2 study results by the lead investigator, Dr. Pedram Hamrah.

👉 The presentation is scheduled for Saturday, April 11, 2026, from 3:30 PM to 5:00 PM. This dual presence is framed as an important milestone to refine strategy.

📊 Clinical Trial Status & What's Next

Urcosimod has already shown promising results:

A Phase 2 trial for dry eye disease showed clear statistical success.
A more recent Phase 2 trial for NCP (with 18 patients) showed positive pain reduction and was well-tolerated.

👉 The next major step is to start a larger, 150-patient Phase 2b/3 study for NCP in the first half of 2026. This conference and advisory board meeting are key to finalizing the design of that crucial trial.

🌍 Industry Context & Signals

This update is about building credibility and momentum. Presenting at a major conference like ASCRS puts their data before key opinion leaders in ophthalmology. The dedicated SAB meeting shows they are actively seeking expert input to strengthen their clinical development plan.

👉 For investors, this signals the company is executing its plan to advance urcosimod toward later-stage trials, which is a critical value-creating period for a clinical-stage biotech.

⚖️ Big Picture: Strengths & Risks

👍 Strengths: Clear focus on a condition with high unmet need; positive early clinical data; FDA Fast Track status; and active engagement with the scientific community.
⚠️ Risks: As a clinical-stage company, OKYO is pre-revenue and faces the inherent risk that larger Phase 2b/3 trials may not confirm the early promise. Their success is entirely dependent on the continued development and eventual approval of urcosimod.

🧠 The Analogy

OKYO Pharma is like a startup chef who has created a promising new recipe (urcosimod) that has won over a few taste-testers (Phase 2 trials). Now, they are presenting that recipe at a big food critics' conference (ASCRS) and holding a private tasting panel with master chefs (the SAB) to perfect it before launching it in a massive, public cooking competition (the Phase 2b/3 trial).

🧩 Final Takeaway

This filing announces OKYO's strategic push to leverage a major ophthalmology conference to validate its lead drug, urcosimod, and finalize plans for the pivotal late-stage study needed to bring a first-of-its-kind NCP treatment closer to patients.

OKYO Pharma Ltd — 6-K Filing